RSS Alerts

Latest News

  • Freeze or run? Not that simple
    Fear can make you run or fight, or it can glue you to the spot. Now, scientists have identified the part of the brain and the type of neurons that determine how mice react to a frightening stimulus.
  • Body clock drugs could ease psychiatric disorders
    Researchers have used a drug to reset and restart the 24 hour body clock of mice, which could eventually help with human difficulties including some psychiatric disorders, jet lag and the health impacts of shift work.
  • Scientists uncover Achilles heel of chronic inflammatory pain
    Researchers have made a discovery that could lead to a brand new class of drugs to treat chronic pain caused by inflammatory conditions, such as arthritis and back pain, without numbing the whole body.
  • Spindle maintenance machinery identified
    During cell division, microtubules emanating from each of the spindle poles meet and overlap in the spindle’s mid zone. Now, scientists have uncovered the molecular mechanism that determines the extent of this overlap.
  • Supply and demand
    Scientists at the European Molecular Biology Laboratory have discovered that a group of proteins named IRPs ensure that the iron balance is maintained in cells and, as such, are essential for cell survival.
view more

Podcasts

  • Evotec strengthens and expands its Alliance Business
    Dr Mark Ashton is Executive Vice President, Business Development of Evotec and is responsible for Evotec's commercial and partnering activities. Prior to assuming responsibility for Business Development in 2005, Dr Ashton held a number of positions within Operations at Evotec: He joined the Company in 1995 as one of the initial employees of the Discovery Division, becoming Department Manager in 2001, Director of Chemistry Services in 2002 and taking over responsibility for Evotec's Discovery Services Division in 2004, where he had responsibility for Evotec's screening, parallel synthesis and medicinal chemistry operations. During his time at Evotec, Dr Ashton has managed a wide range of pharmaceutical and biotechnology related projects, including medicinal chemistry projects, design and synthesis of screening libraries and technology transfer projects and has been involved in the progression of a number of drug candidates into the clinic in numerous therapeutic areas. Dr Ashton has authored and co-authored a number of peer reviewed papers, articles and book chapters in addition to being named on a number of pharmaceutical patents. He is trained as a medicinal chemist. Prior to joining Evotec, Dr Ashton also had spells at ICI Pharmaceuticals and Organon Laboratories. Mark Whittaker is Senior Vice President Drug Discovery at Evotec where he manages a large drug discovery collaboration and the groups of computational chemistry and structural biology. Before joining Evotec in 2001, Mark spent 13 years at British Biotech Pharmaceuticals where he led a number of medicinal chemistry programmes and was latterly Director of Chemistry. At British Biotech, Mark contributed to the discovery and development of six compounds that have progressed into human clinical trials. Before his career at British Biotech, Mark carried out post-doctoral research at the University of Oxford and at York University, Toronto and obtained a D. Phil in Chemistry from the University of York.
  • The Ubiquitin Story
    In this podcast interview with Drug Discovery Today, Nobel Prize winner Professor Aaron Ciechanover will talk about his career, his Nobel Prize-winning discovery of the UPS, and the extraordinary opportunities and challenges for drug discovery in this area.
  • Califf, Behrman and Kramer discuss the Clinical Trials Transformation Initiative.
    Download the Califf, Behrman and Kramer podcast as an mp3 file
  • Dr Brent Vose outlines AstraZeneca's oncology pipeline.
    Download the Dr. Brent Vose podcast as an mp3 file
view more

Webinars

view more

Features

  • Most downloaded review Q1 2009: Target discovery from data mining approaches
    The most downloaded review article from Drug Discovery Today from the first quarter of 2009 deals with the topic of target discovery from the informatics perspective. It would be difficult to overstate the value to Pharma of identifying and validating the most relevant therapeutic targets. In this article, Yang, Adelstein and Kassis outline text mining, its value and limitations and application to target discovery. In addition, they cover the field of emerging and integrated data mining approaches.
view more

25 Hottest Articles

view more
Copyright © 2010
Elsevier Ltd. All rights reserved.
Terms & Conditions | Privacy | Website Design Working with water